A fter its introduction to the clinical arena more than 20 years ago (1, 2) , fractional flow reserve (FFR) has become an increasingly utilized tool for optimizing revascularization decisions in patients with coronary artery disease (3) (4) (5) (6) .
However, despite the evidence base from large randomized trials, registries, and clinical guideline recommendations (7), FFR is not universally adopted.
Some of the reasons for this discord relate to cost, difficulty interpreting FFR in certain clinical situations, as well as issues relating to the drugs required for the procedure. Such issues have prompted other researchers to look to 'drug free' indexes to assess stenosis severity (8) .
The use of FFR is predicated on the induction of maximal hyperemia such that measures of pressure become proportional to coronary blood flow (9).
Adenosine is one of the most commonly used drugs to achieve hyperemia in the catheter laboratory.
Both intracoronary (IC) and intravenous (IV) methods of delivering adenosine are capable of producing hyperemia, although the IV method is regarded as the current gold standard (10) . However, although the IV route poses several practical advantages, such as the potential to perform a pressure wire pullback in situations of tandem lesions or diffusely diseased coronary arteries, IV adenosine administration can be more time-consuming and costly due to the larger amount of adenosine required for FFR assessment.
Thus, the IC route is potentially a more attractive option in the assessment of FFR.
Earlier studies had suggested a maximal IC dose of adenosine of 16 mg for the left coronary artery and 12 mg for the right coronary artery (11) with increasing doses of 2 orders of magnitude to ensure maximal vasodilation (12) . These protocols were challenged by animal data suggesting that higher doses of adenosine may be needed to achieve maximal hyperemia (13) and clinical studies that suggested that standard adenosine dosing failed to achieve maximal hyperemia compared with papaverine and IV adenosine (10, 14) . Current recommendations for IC adenosine dosing are 40 mg in the right coronary artery and 60 mg in the left coronary artery, increasing the doses incrementally by 30 mg to a maximum of 150 mg (15) . reported that he has no relationships relevant to the contents of this paper to disclose. Although these results are informative, the study is limited by the small sample size and the use of a normalized flow velocity in relation to the highest dose of adenosine (500 mg) as the reference standard.
An alternative method would have been to also use IV adenosine and use this as a reference standard.
Despite these minor shortcomings, the study adds to the weight of evidence that IC adenosine is adequate for achieving a sufficient hyperemic response in most patients. Furthermore, due to its ease of use and lack of side effects for patients, it may be the preferred route of delivery when more complex assessments relating to diffuse disease, tandem stenosis, and microvascular function are not required.
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